The researchers used Epidiolex,
the first FDA-approved cannabis-based medication, as their source of CBD.
With many CBD products on the market now the exact concentration of CBD is uknown. In addition, they may have additives such as pesticides and even lead. But, Hurd said, with Epidiolex the exact concentration and other ingredients in the drug is known, which was key. “We are developing a medicine. We are not developing a recreational cannabis,” she said.
Participants reported very few bad reactions, such as mild diarrhea, headache and tiredness.
These findings are similar to those of a pilot study Hurd ran, but she says the next step is to do a longer-term study, following subjects for up to six months.
The study’s potential was not lost on others.
“This is an extremely significant paper. We need to utilize every possible treatment in helping people with chronic pain to find other ways to manage their symptoms and in people with opiate addiction to find relief,” said Dr. Julie Holland,
a psychiatrist in New York and former assistant professor of psychiatry at the New York University School of Medicine.